and I hope they get it to market before us coz it will be set as a precedent for any future approval.... the more flexible FDA is the better chances of us making it to market...
And if we make the market, with our safety profile we will have plenty of opportunities...
I know first to market has advantages but in this case it's making to market that's key given the safety challenges of the other product
Ann: FSGS Study, Partnering & Commercialisation Investor Briefing, page-104
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
-0.025(5.62%) |
Mkt cap ! $231.2M | |||
| Open | High | Low | Value | Volume |
| 43.5¢ | 44.0¢ | 41.8¢ | $1.239M | 2.905M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 257588 | 42.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.5¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| DXB (ASX) Chart |